Resistance to anti-tubulin agents: From vinca alkaloids to epothilones

Abstract

This review describes the mechanism of action - inhibition of microtubules - and the most important mechanisms of resistance for vinca alkaloids, taxanes and epothilones. Resistance is a major problem in vinca and taxane chemotherapy and arises in most cases from overexpression of efflux pumps that transport the drugs out of the cancer cells and from modifications of the target, the microtubules, by overexpression of tubulin isotypes or by attachment of proteins to the ends of the microtubules so that the target is no longer recognized by the drugs. In some cases, however, this process can have the opposite effect, leading to sensitization, e.g., for vinca alkaloids in cases where taxanes are not or no longer effective. The link between resistance due to efflux pumps and the pharmacokinetics and metabolism of the drugs is also covered. Other types of resistance that are addressed include detoxification of drugs within the cancer cell and blockade of apoptosis, post-translational modifications of microtubules and other protein pathways, micro-RNAs, induction of oncogenes, and cancer stem cells, which, taken together, offer particularly multifold possibilities for preventing drug activity. The use of biomarkers for the prediction of clinical outcome and for the direction of future therapy is also addressed.

Keywords

Microtubules / tumor heterogeneity / mechanisms of resistance / cancer stem cells / biomarkers / pharmacokinetics / metabolism

References

[1] Akhmanova A.Control of microtubule organization and dynamics: two ends in the limelight..Nat Rev Mol Cell Biol2015;16:711-26

[2] Yang CH.Taxol®: the first microtubule stabilizing agent..Int J Mol Sci2017;18:E1733 PMCID:PMC5578123

[3] Lewis SA,Cowan NJ.Five mouse tubulin isotypes and their regulated expression during development..J Cell Biol1985;101:852-61 PMCID:PMC2113702

[4] Denoulet P,Gros F.Differential expression of several neurospecific beta-tubulin mRNAs in the mouse brain during development..Gene1986;50:289-97

[5] Yu I,Roll-Mecak A.Writing and Reading the Tubulin Code..J Biol Chem2015;290:17163-72 PMCID:PMC4498056

[6] Janke C.Causes and consequences of microtubule acetylation..Curr Biol2017;27:R1287-92

[7] Hammond JW,Verhey KJ.Tubulin modifications and their cellular functions..Curr Opin Cell Biol2008;20:71-6 PMCID:PMC2274889

[8] Verhey KJ.The tubulin code..Cell Cycle2007;6:2152-60

[9] Westermann S.Post-translational modifications regulate microtubule function..Nat Rev Mol Cell Biol2003;4:938-47

[10] Cambray-Deakin MA.Posttranslational modifications of α-tubulin: acetylated and detyrosinated forms in axons of rat cerebellum..J Cell Biol1987;104:1569-74 PMCID:PMC2114518

[11] Paturle L,Margolis RL.Complete separation of tyrosinated, detyrosinated, and nontyrosinatable brain tubulin subpopulations using affinity chromatography..Biochemistry1989;28:2698-704

[12] Eddé B,Le Caer JP,Gros F.Posttranslational glutamylation of alpha-tubulin..Science1990;247:83-5

[13] Rogowski K,Magiera MM,Deloulme JC.A family of protein-deglutamylating enzymes associated with neurodegeneration..Cell2010;143:564-78

[14] Erck C,Andrieux A,Gruber AD.A vital role of tubulin-tyrosine-ligase for neuronal organization..Proc Natl Acad Sci USA2005;102:7853-8 PMCID:PMC1129054

[15] Ikegami K,Taruishi M,Mukai M.Loss of β-tubulin polyglutamylation in ROSA22 mice is associated with abnormal targeting of KIF1A and modulated synaptic function..Proc Natl Acad Sci USA2007;104:3213-8 PMCID:PMC1802010

[16] Farache D,Haren L.Assembly and regulation of γ-tubulin complexes..Open Biol2018;8:170266 PMCID:PMC5881034

[17] Caplow M.Dissociation of the tubulin dimer is extremely slow, thermodynamically very unfavorable, and reversible in the absence of an energy source..Mol Biol Cell2002;13:2120-31 PMCID:PMC117629

[18] Hiller G.Radioimmunoassay for tubulin: a quantitative comparison of the tubulin content of different established tissue culture cells and tissues..Cell1978;14:795-804

[19] Nogales E.Structural insights into microtubule function..Annu Rev Biochem2000;69:277-302

[20] Luduena RF.A hypothesis on the origin and evolution of tubulin..Int Rev Cell Mol Biol2013;302:41-185

[21] Fees CP.Regulation of microtubule dynamic instability by the carboxy-terminal tail of β-tubulin..Life Sci Alliance2018;1:e201800054 PMCID:PMC6022761

[22] Jordan MA.Mechanism of action of antitumor drugs that interact with microtubules and tubulin..Curr Med Chem Anticancer Agents2002;2:1-17

[23] Inoué S.Cell motility by labile association of molecules. The nature of mitotic spindle fibers and their role in chromosome movement..J Gen Physiol1967;50:259-92 PMCID:PMC2225745

[24] Mitchison T.Dynamic instability of microtubule growth..Nature1984;312:237-42

[25] Cassimeris L.Accessory protein regulation of microtubule dynamics throughout the cell cycle..Curr Opin Cell Biol1999;11:134-41

[26] Kreis T.Guidebook to the cytoskeleton and motor proteins.1999;London/New YorkOxford Univ. Press

[27] Ohi R.Ahead of the curve: new insights into microtubule dynamics..F1000Res2016;5:314-22 PMCID:PMC4786905

[28] Valiron O,Job D.Microtubule dynamics..Cell Mol Life Sci2001;58:2069-84

[29] Pepperkok R,Davoust J.Microtubules are stabilized in confluent epithelial cells but not in fibroblasts..J Cell Biol1990;111:3003-12 PMCID:PMC2116362

[30] Saxton WM,Leslie RJ,Zavortink M.Tubulin dynamics in cultured mammalian cells..J Cell Biol1984;99:2175-86 PMCID:PMC2113582

[31] Rusan NM,Yvon AM.Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-α tubulin..Mol Biol Cell2001;12:971-80 PMCID:PMC32280

[32] Correia JJ.Physiochemical aspects of tubulin-interacting antimitotic drugs..Current Pharmaceutical Design2001;7:1213-28

[33] Visconti R.Fighting tubulin-targeting anticancer drug toxicity and resistance..Endocr Relat Cancer2017;24:T107-17

[34] Tame MA,Belokhvostova D,Medema RH.TUBB3 overexpression has a negligible effect on the sensitivity to taxol in cultured cell lines..Oncotarget2017;8:71536-47 PMCID:PMC5641069

[35] Alkadi H,Jbeily R.Colchicine: a review on chemical structure and clinical usage..Infect Disord Drug Targets2018;18:105-21

[36] Rao CV,Yamada HY.Mitosis-targeting natural compounds for cancer prevention and therapy..Curr Drug Targets2012;13:1820-30

[37] Downing KH.New insights into microtubule structure and function from the atomic model of tubulin..Eur Biophys J1998;27:431-6

[38] Dumontet C.Microtubule-binding agents: a dynamic field of cancer therapeutics..Nat Rev Drug Discov2010;9:790-803 PMCID:PMC3194401

[39] Moudi M,Seok Yien CY.Vinca alkaloids..Int J Prev Med2013;4:1231-5 PMCID:PMC3883245

[40] Downing KH.Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics..Annu Rev Cell Dev Biol2000;16:89-111

[41] Silverman JA.Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine..Cancer Chemother Pharmacol2013;71:555-64 PMCID:PMC3579462

[42] Silvestri R.New prospects for vinblastine analogues as anticancer agents..J Med Chem2013;56:625-7

[43] Carlson RO.New tubulin targeting agents currently in clinical development..Expert Opin Invest Drugs2008;17:707-22

[44] Blume E.Investigators Seek to Increase Taxol Supply..J National Cancer Institute1989;81:1122-3

[45] Parness J.Taxol binds to polymerized tubulin in vitro..J Cell Biol1981;91:479-87 PMCID:PMC2111958

[46] Diaz JF.Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition..Biochemistry1993;32:2747-55

[47] Manfredi JJ,Horwitz SB.Taxol binds to cellular microtubules..J Cell Biol1982;94:688-96 PMCID:PMC2112233

[48] Abal M,Barasoain I.Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action..Curr Cancer Drug Targets2003;3:193-203

[49] Field JJ,Calvo E,Zurwerra D.Zampanolide, a potent new microtubule-stabilizing agent, covalently reacts with the taxane luminal site in tubulin α,β-heterodimers and microtubules..Chem Biol2012;19:686-98 PMCID:PMC3383615

[50] Schiff PB,Horwitz SB.Promotion of microtubule assembly in vitro by taxol..Nature1979;277:665-7

[51] Orr GA,McDaid H.Mechanisms of taxol resistance related to microtubules..Oncogene2003;22:7280-95 PMCID:PMC4039039

[52] Diaz JF,Chacon P,Andreu JM.Changes in microtubule protofilament number induced by Taxol binding to an easily accessible site. Internal microtubule dynamics..J Biol Chem1998;273:33803-10

[53] Wang Z.Taxane resistance in breast cancer..Can Cell Microenviron2014;1:e126

[54] Ferlini C,Raspaglio G,Cimitan S.Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77..Cancer Res2009;69:6906-14

[55] Ganguly A,Cabral F.Paclitaxel dependent cell lines reveal a novel drug activity..Mol Cancer Ther2010;9:2914-23 PMCID:PMC2978777

[56] Komlodi-Pasztor E,Fojo AT.Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale..Clin Cancer Res2012;18:51-63

[57] Bogdan C.Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages..J Leukoc Biol1992;52:119-21

[58] Bocci G,Danesi R.The pharmacological bases of the antiangiogenic activity of paclitaxel..Angiogenesis2013;16:481-92 PMCID:PMC3682088

[59] Galsky MD,Kirkpatrick P.Cabazitaxel..Nat Rev Drug Discov2010;9:677-8

[60] Bissery MC.Preclinical evaluation of new taxoids..Curr Pharm Des2001;7:1251-7

[61] Höfle G,Steinmetz H,Gerth K.Epothilone A and B - novel 16-membered macrolides and cytotoxic activity: isolation, crystal structure, and conformation in solution..Angew Chem Int Ed Engl1996;35:1567-9

[62] Krause W.Differences and similarities of epothilones..Current Cancer Therapy Reviews2011;7:10-36

[63] Winsel S.Molecular mode of action and mechanism of resistance of the microtubule-stabilizing drug sagopilone.2009;PhD Thesis, Free University Berlin

[64] Klar U,Giurescu M.Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate..Expert Opin Investig Drugs2008;17:1735-48

[65] Nettles JH,Cornett B,Snyder JP.The binding mode of epothilone A on α, β-tubulin by electron crystallography..Science2004;305:866-9

[66] Bode CJ,Reiff EA,Georg GI.Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules..Biochemistry2002;41:3870-4

[67] Yardley DA.Drug resistance and the role of combination chemotherapy in improving patient outcomes..Int J Breast Cancer2013;2013:137414 PMCID:PMC3707274

[68] Cortes J.Beyond taxanes: the next generation of microtubule-targeting Agents..Breast Cancer Res Treat2012;133:821-30 PMCID:PMC3387492

[69] Mansoori B,Davudian S,Baradaran B.The different mechanisms of cancer drug resistance: a brief review..Adv Pharm Bull2017;7:339-48 PMCID:PMC5651054

[70] Mansoori B,Shirjang S.MicroRNAs in the Diagnosis and Treatment of Cancer..Immunol Invest2017;46:880-97

[71] Gottesman MM.Mechanisms of cancer drug resistance..Ann Rev Medicine2002;53:615-27

[72] Cree IA.Molecular chess? Hallmarks of anti-cancer drug resistance..BMC Cancer2017;17:10-8 PMCID:PMC5214767

[73] Di Nicolantonio F,Knight LA,Whitehouse PA.Cancer cell adaptation to chemotherapy..BMC Cancer2005;5:78-94 PMCID:PMC1199589

[74] BC Cancer. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Vinblastine_monograph_1Feb2015.pdf. [Last accessed on 1 Mar 2019]

[75] BC Cancer. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Vincristine_monograph_1Mar08.pdf. [Last accessed on 1 Mar 2019]

[76] Vindesine. Available from: https://hemonc.org/w/images/3/33/Vindesine.pdf. [Last accessed on 26 Feb 2019]

[77] BC Cancer. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Vinorelbine%20monograph_1Feb2015.pdf. [Last accessed on 1 Mar 2019]

[78] AusPAR: Vinflunine ditartrate. Australian Public Assessment Report, 2011. Available from: https://www.tga.gov.au/auspar/auspar-vinflunine-ditartrate. [Last accessed on 26 Feb 2019]

[79] FDA Label. Available from: https://www.accessdata.fda.gov/drugsatfda/label. [Last accessed on 28 Feb 2019]

[80] Kelly KR,Lozac’h F,Mita A.Metabolism of patupilone in patients with advanced solid tumor malignancies..Invest New Drugs2013;31:605-15

[81] European Medicines Agency. Withdrawal assessment report for Ixempra. Available from: https://www.ema.europa.eu/documents/withdrawal-report/withdrawal-assessment-report-ixempra_en.pdf. [Last accessed on 28 Feb 2019]

[82] Konner J,Park J,Cropp G.Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma..Invest New Drugs2012;30:2294-302 PMCID:PMC4003559

[83] Lam ET,Schaaf LJ,Hannah AL.Phase I dose escalation study of KOS 1584, a novel epothilone, in patients with advanced solid tumors..Cancer Chemother Pharmacol2012;69:523-31 PMCID:PMC3865603

[84] Xie HG,Kim RB,Wilkinson GR.Genetic variability in CYP3A5 and its possible consequences..Pharmacogenomics2004;5:243-72

[85] Silverman JA,Deitcher SR.Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia..J Clin Pharmacol2013;53:1139-45

[86] Ohishi Y,Basaki Y,Wake N.Expression of β-tubulin isotypes in human primary ovarian carcinoma..Gynecol Oncol2007;105:586-92

[87] Izutsu N,Shibazaki M,Shoji T.Epigenetic modification is involved in aberrant expression of class III β-tubulin, TUBB3, in ovarian cancer cells..Int J Oncol2008;32:1227-35

[88] Du J,Fang Y,Wang Y.Overexpression of class III beta-tubulin, sox2, and nuclear survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer..BMC Cancer2015;15:536-47 PMCID:PMC4511538

[89] Roque DM,English DP,Cocco E.Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones..Cancer2013;119:2582-92 PMCID:PMC3700638

[90] Ullah MF.The footprints of cancer development: cancer biomarkers..Cancer Treat Rev2009;35:193-200

[91] Gottesman MM,Bates SE.Multidrug resistance in cancer: role of ATP-dependent transporters..Nat Rev Cancer2002;2:48-58

[92] Safa AR.Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators..Curr Med Chem Anticancer Agents2004;4:1-17 PMCID:PMC4447203

[93] Manzoor S,Khan S,Iftikhar S.Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistance..Sci Rep2018;8:3305 PMCID:PMC5818492

[94] Fojo T.Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents..Ann Oncol2007;18:3-8

[95] Su DS,Meng D,Danishefsky SJ.Structure-activity Relationships of the epothilones and the first in vivo comparison with paclitaxel..Angew Chem Int Ed Engl1997;36:2093-6

[96] Chou TC,Tong WP,Zhang ZG.The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice..Proc Natl Acad Sci USA2001;98:8113-8 PMCID:PMC35476

[97] Horwitz SB,Rao S,Shen HJ.Taxol: mechanisms of action and resistance..J Natl Cancer Inst Monogr1993;1555-61

[98] Jachez B,Loor F.Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446..J Natl Cancer Inst1993;85:478-83

[99] Grogan TM,Salmon SE,Rybski J.P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy..Blood1993;81:490-5

[100] Dalton WS,Salmon SS,Laufman LR.A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study..Cancer1995;75:815-20

[101] Koushik OS,Kumar P.Nano drug delivery systems to overcome cancer drug resistance - a review..J Nanomed Nanotechnol2016;7:378

[102] Cisternino S,Archimbaud Y,Sanderink G.Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats..Brit J Pharmacol2003;138:1367-75 PMCID:PMC1573768

[103] Hopper-Borge E,Shen T,Chen ZS.Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B..Cancer Res2009;69:178-84 PMCID:PMC2745904

[104] Lin JH.Clinical relevance of P-Glycoprotein in drug therapy..Drug Metab Rev2003;35:417-54

[105] Guo HQ,Wang YJ,Sodani K.β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by theABCB1 transporter..Oncology Reports2014;31:858-66

[106] Loe DW,Deeley RG.Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport..J Biol Chem1996;271:9675-82

[107] Kitazono M,Takebayashi Y,Furukawa T.Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells..J Nat Cancer Inst1999;91:1647-53

[108] Izquierdo MA,Vermorken J,Belien JA.Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma..J Natl Cancer Inst1995;87:1230-6

[109] Parker AL,McCarroll JA.An emerging role for tubulin isotypes in modulating cancer biology and chemotherapy resistance..Int J Mol Sci2017;18:1434-58 PMCID:PMC5535925

[110] Vilmar A,Huarriz M,Sorensen JB.RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC..Lung Cancer2012;75:306-12

[111] Iseri OD,Gunduz U.Drug resistant MCF-7 cells have altered expression levels of beta-tubulin isotypes and mutations in TUBB gene..Int J Hematol Oncol2010;2:75-83

[112] Freedman H,Luchko T,Tuszynski JA.Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity..J Chem Inf Model2009;49:424-36

[113] Kavallaris M,Burkhart CA,Norris MD.Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes..J Clin Invest1997;100:1282-93 PMCID:PMC508306

[114] Mozzetti S,Concolino P,Raspaglio G.Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients..Clin Cancer Res2005;11:298-305

[115] Ferrandina G,Martinelli E,Gallotta V.Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients..Clin Cancer Res2006;12:2774-9

[116] Su D,Preti M,Rutherford TJ.Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel..Cancer2009;115:2453-63

[117] De Donato M,Petrella L,Zannoni GF.Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer..J Cell Physiol2012;227:1034-41

[118] Roque DM,Glasgow M,Bortolomai I.Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel..Clin Exp Metastasis2014;31:101-10 PMCID:PMC3947146

[119] Parker AL,McCarroll JA.βIII-Tubulin alters glucose metabolism and stress response signaling to promote cell survival and proliferation in glucose-starved non-small cell lung cancer cells..Carcinogenesis2016;37:787-98

[120] Raspaglio G,Prislei S,De Maria I.Hypoxia induces class III β-tubulin gene expression by HIF-1α binding to its 3′ flanking region..Gene2008;409:100-8

[121] Bordji K,Cuhna-Alves L,Bernaudin M.Hypoxia-inducible factor-2 (HIF-2), but not HIF-1, is essential for hypoxic induction of class III β-tubulin expression in human glioblastoma cells..FEBS J2014;281:5220-36

[122] Raspaglio G,Filippetti F,Zannoni GF.Hur regulates β-tubulin isotype expression in ovarian cancer..Cancer Res2010;70:5891-900

[123] Patel VP.Decreased SIRT2 activity leads to altered microtubule dynamics in oxidatively-stressed neuronal cells: Implications for Parkinson’s disease..Exp Neurol2014;257:170-81 PMCID:PMC4141566

[124] Drum BML,Li L,Wordeman L.Oxidative stress decreases microtubule growth and stability in ventricular myocytes..J Mol Cell Cardiol2016;93:32-43 PMCID:PMC4902331

[125] Azuma K,Kawahara A,Hattori S.Expression of ERCC1 and ulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel..Lung Cancer2009;64:326-33

[126] Karki R.Class III beta-tubulin, drug resistance, therapeutic approaches in cancers..Atlas Genet Cytogenet Oncol Haematol2014;18:865-71

[127] Aoki D,Hattori S,Ohishi Y.Overexpression of class III β-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma..Clin Cancer Res2009;15:1473-80

[128] Wang Y,Fineberg S,Sunkara J.High expression of class III beta-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer..Clin Breast Cancer2013;13:103-8 PMCID:PMC4039021

[129] Mozzetti S,de Maria I,Mariani M.Molecular mechanisms of patupilone resistance..Cancer Res2008;68:10197-204

[130] Magnani M,Soro S,Tramontano A.The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies..FEBS J2006;273:3301-10

[131] Ferlini C,Mozzetti S,Filippetti F.The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance..Cancer Res2005;65:2397-405

[132] Ferrandina G,Andreoli M,Scambia G.Novel Drugs Targeting Microtubules: the Role of Epothilones..Curr Pharm Des2012;18:2793-803

[133] Kavallaris M,Horwitz SB.Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol..Br J Cancer1999;80:1020-5 PMCID:PMC2363042

[134] Miyamoto DT,Mitchison TJ.Dynamics of the mitotic spindle - potential therapeutic targets..Prog Cell Cycle Res2003;5:349-60

[135] Kanakkanthara A,Miller JH.βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells..Mol. Cancer Ther2012;11:393-404

[136] Gan PP,Po’uha ST,Jordan MA.Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin..Mol Cancer Ther2010;9:1339-48

[137] Gan PP.Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity..Cancer Res2008;68:9817-24

[138] Sharbeen G,Liu J,Limbri LF.Delineating the role of βIV-tubulins in pancreatic cancer: βIVb-tubulin inhibition sensitizes pancreatic cancer cells to vinca alkaloids..Neoplasia2016;18:753-64 PMCID:PMC5126129

[139] Narvi E,Winsel S,Halonen P.Altered TUBB3 expression contributes to the epothilone response of mitotic cells..Br J Cancer2013;108:82-90 PMCID:PMC3553534

[140] Bhattacharya R.A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation..Mol Biol Cell2004;15:3123-31 PMCID:PMC452570

[141] Hari M,Zeng C,Cabral F.Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel..Cell Motil Cytoskelet2003;56:45-56

[142] Blade K,Cabral F.Overexpression of class I, II or IVb β-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel..J Cell Sci1999;112:2213-21

[143] Ranganathan S,Dexter DW.Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells..Br J Cancer2001;85:735-40 PMCID:PMC2364133

[144] Jordan MA.Microtubules as a target for anticancer drugs..Nat Rev Cancer2004;4:253-65

[145] Tsourlakis MC,Grupp K,Steurer S.βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion..Am J Pathol2014;184:609-17

[146] Thiery JP,Huang RY.Epithelial-mesenchymal transitions in development and disease..Cell2009;139:871-90

[147] Sobierajska K,Ciszewski WM,Wawro ME.β-III tubulin modulates the behavior of snail overexpressed during the epithelial-to-mesenchymal transition in colon cancer cells..Biochim Biophys Acta2016;1863:2221-33

[148] McGrogan BT,Carney DN.Taxanes, microtubules and chemoresistant breast cancer..Biochim Biophys Acta2008;1785:96-132

[149] Kavallaris M.Microtubules and resistance to tubulin- tubulin-binding agents..Nat Rev Cancer2010;10:194-204

[150] Rouzier R,Wagner P,Gold DL.Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer..Proc Natl Acad Sci USA2005;102:8315-20 PMCID:PMC1149405

[151] Cabral FR,Schibler MJ.A mechanism of cellular resistance to drugs that interfere with microtubule assembly..Ann NY Acad Sci1986;466:745-56

[152] Cabral F.Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly..FASEB J1989;3:1593-9

[153] Minotti AM,Cabral F.Resistance to antimitotic drugs in Chinese hamster ovary cells correlated with changes in the level of polymerized tubulin..J Biol Chem1991;266:3987-94

[154] Derry WB,Jordan MA.Substoichiometric binding of taxol suppresses microtubule dynamics..Biochemistry1995;34:2203-11

[155] Wilson L.Microtubule dynamics: taking aim at a moving target..Chem Biol1995;2:569-73

[156] Jordan MA.Microtubules and actin filaments: dynamic targets for cancer chemotherapy..Curr Opin Cell Biol1998;10:123-30

[157] Goncalves A,Kamath K,Briand C.Resistance to taxol in lung cancer cells associated with increased microtubule dynamics..Proc Natl Acad Sci USA2001;98:11737-41 PMCID:PMC58799

[158] Giannakakou P,Kang YK,Buters JT.Paclitaxel resistant human ovarian cancer cells have mutant beta- tubulins that exhibit impaired paclitaxel-driven polymerization..J Biol Chem1997;272:17118-25

[159] Zhong S,Wang D,Shen H.MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes..Oncotarget2016;7:19601-9 PMCID:PMC4991404

[160] Fang Y,Fu Y.MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling..J Biol Res (Thessalon)2015;22:12 PMCID:PMC4619013

[161] Hu W,He Y,Xu Y.Functional miRNAs in breast cancer drug resistance..Onco Targets Ther2018;11:1529-41 PMCID:PMC5865556

[162] Zhu X,Xie C,Liu Y.miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6..Int J Cancer2014;135:1286-96

[163] Li H,Sun X,Shi C.MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells..Int J Oncol2015;47:1379-92

[164] Naghizadeh S,Mohammadi A,Baradaran B.Gene silencing strategies in cancer therapy: an update for drug resistance..Curr Med Chem2018;

[165] Higgins CF.ABC transporters: from microorganisms to man..Annu Rev Cell Biol1992;8:67-113

[166] de Vree JM,Sturm E,Bosma PJ.Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis..Proc Natl Acad Sci USA1998;95:282-7 PMCID:PMC18201

[167] Murray S,Linardou H,Papadimitriou C.Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies..Cancer Treat Rev2012;38:890-903

[168] Kienitz A,Morales I,Bastians H.Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol..Oncogene2005;24:4301-10

[169] Carvalho A,Sambade C,Wheatley SP.Survivin is required for stable checkpoint activation in taxol-treated HeLa cells..J Cell Sci2003;116:2987-98

[170] Chen X,Wang W.Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3..Biochem Biophys Res Commun2000;277:757-63

[171] Wahl AF,Fairchild C,Foster SA.Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis..Nat Med1996;2:72-9

[172] Shitashige M,Yano T,Matsuo Y.Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2..J Biochem2001;130:741-8

[173] Bhalla KN.Microtubule-targeted anticancer agents and apoptosis..Oncogene2003;22:9075-86

[174] Genovese I,Battista T,Fazi F.Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents..Cancer Drug Resists2018;1:164-80

[175] Hu Y,Yang M,Fan D.Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo..Breast Cancer Res Treat2014;143:287-99

[176] Lalioti VS,O’Connell DJ,Sandoval IV.Sorcin links calcium signaling to vesicle trafficking, regulates Pololike kinase 1 and is necessary for mitosis..PLoS One2014;9:e85438 PMCID:PMC3888430

[177] Maddalena F,Lettini G,Matassa DS.Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1..Mol Oncol2013;7:895-906 PMCID:PMC5528458

[178] Maddalena F,Piscazzi A,Scorziello A.Sorcin induces a drug-resistant phenotype in human colorectal cancer by modulating Ca(2+) homeostasis..Cancer Res2011;71:7659-69

[179] Colotti G,Fiorillo A,Chiarini V.Sorcin, a calcium binding protein involved in the multidrug resistance mechanisms in cancer cells..Molecules2014;19:13976-89 PMCID:PMC6271628

[180] Gao Y,Liu X,Zhao X.Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells..Mol Med Rep2015;11:2118-24

[181] Hu Y,Li S,Wang J.Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins..Cancer Chemother Pharmacol2013;72:789-98

[182] Gong J,Liu D.F-box proteins involved in cancer-associated drug resistance (Review)..Oncol Lett2018;15:8891-900 PMCID:PMC5958692

[183] Hershko DD.Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer..Cancer2008;112:1415-24

[184] Wertz IE,Lam C,Sandoval W.Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7..Nature2011;471:110-4

[185] Yokobori T,Iwatsuki M,Onoyama I.p53-altered FBXW7 expression determines poor prognosis in gastric cancer cases..Cancer Res2009;69:3788-94

[186] Yeh CH,Nicot C.FBXW7: a critical tumor suppressor of human cancers..Molecular Cancer2018;17:115 PMCID:PMC6081812

[187] Xu Y,Kukreja L.MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7..J Biol Chem2010;285:34439-46 PMCID:PMC2966058

[188] Mozzetti S,Raspaglio G,De Donato M.Gli family transcription factors are drivers of patupilone resistance inovarian cancer..Biochem Pharmacol2012;84:1409-18

[189] Katayama K,Sugimoto Y.FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin-proteasome pathway in cancer cells..Cancer Sci2013;104:694-702

[190] Kreitzburg KM,Yoon KJ.Sphingolipid metabolism and drug resistance in ovarian cancer..Cancer Drug Resist2018;1:181-97

[191] Dobbin ZC,Steg AD,Shah MM.Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer..Oncotarget2014;5:8750-64 PMCID:PMC4226719

[192] Swanton C,Pardo O,Kelly G.Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs..Cancer Cell2007;11:498-512

[193] Prinetti A,D’Ascenzo S,Bettiga A.Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells..Biochem J2006;395:311-8 PMCID:PMC1422777

[194] Al-Hajj M,Benito-Hernandez A,Clarke MF.Prospective identification of tumorigenic breast cancer cells..PNAS2003;100:3983-8 PMCID:PMC153034

[195] Singh SK,Terasaki M,Hawkins C.Identification of a cancer stem cell in human brain tumors..Cancer Res2003;63:5821-8

[196] Lapidot T,Vormoor J,Hoang T.A cell initiating human acute myeloid leukaemia after transplantation into SCID mice..Nature1994;367:645-8

[197] Liu FS.Mechanisms of chemotherapeutic drug resistance in cancer therapy - a quick review..Taiwan J Obstet Gynecol2009;48:239-44

[198] Kelly PN,Adams JM,Strasser A.Tumor growth need not be driven by rare cancer stem cells..Science2007;317:37

[199] Mansoori M,Janani L.Circulating cancer stem cell markers in breast carcinomas: a systematic review protocol..Syst Rev2017;6:262 PMCID:PMC5738150

[200] Yu Z,Lisantic MP.Cancer stem cells..Int J Biochem Cell Biol2012;44:2144-51 PMCID:PMC3496019

[201] Lou H.Targeted therapy for cancer stem cells: the patched pathway and ABC transporters..Oncogene2007;26:1357-60

[202] Bourguignon LYW,Xia W.Hyaluronan-CD44 interaction activates stem cell marker, Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells..J Biol Chem2008;283:17635-51 PMCID:PMC2427357

[203] Ruxrungtham K,Buranapraditkun S.Alemtuzumab-induced elimination of HIV-1-infected immune cells..J Virus Erad2016;2:12-8 PMCID:PMC4946689

[204] Hennenfent KL.Novel formulations of taxanes: a review. Old wine in a new bottle?.Ann Oncol2006;17:735-49

[205] Ma P.Paclitaxel nano-delivery systems: a comprehensive review..Nanomed Nanotechnol2013;4:1000164 PMCID:PMC3806207

[206] Ojima I,Lee S,Wang X.Taxane anticancer agents: a patent perspective..Expert Opin Ther Pat2016;26:1-20 PMCID:PMC4941984

[207] Régina A,Ché C,Poirier J.Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2..Br J Pharmacol2008;155:185-97 PMCID:PMC2538693

[208] Mooberry SL,Hernandez AH,Davidson BS.Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents..Cancer Res1999;59:653-60

[209] Churchill CDM,Tuscynski JA.Analysis of the binding mode of laulimalide to microtubules: establishing a laulimalide-tubulin pharmacophore..J Biomol Struct Dyn2015;34:1-35

[210] Bennett MJ,Rattner JB,Schriemer DC.Low-dose laulimalide represents a novel molecular probe for investigating microtubule organization..Cell Cycle2012;11:3045-54

[211] Pryor DE,Bilcer G,Wang Y.The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity..Biochemistry2002;41:9109-15

[212] Hamel E,Miller JH,Northcote PT.Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly..Mol Pharmacol2006;70:1555-64

[213] Kanakkanthara A,Miller JH.Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune disease..Nat Prod Rep2016;33:549-61

[214] Ganguly A,Yang H.Peloruside A is a microtubule-stabilizing agent with exceptional anti-migratory properties in human endothelial cells..Oncoscience2015;2:585-95 PMCID:PMC4506362

[215] Gunasekera SP,Longley RE.Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta..J Org Chem1990;55:4912-5

[216] Martello LA,Regl DL,Meng D.Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines..Clin Cancer Res2000;6:1978-87

[217] Mita A,Chen TL,Curtright J.A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies..J Clin Oncol2004;22:2025

[218] Tanaka J.Zampanolide, a new cytotoxic macrolide from a marine sponge..Tetrahedron Lett1996;37:5535-8

[219] Field JJ,Calvo E,Zurwerra D.Zampanolide, a potent new microtubule stabilizing agent, covalently reacts with the taxane luminal site in both tubulin α,β-heterodimers and microtubules..Chem Biol2012;19:686-98 PMCID:PMC3383615

[220] Chen QH.Zampanolide and dactylolide: cytotoxic tubulin-assembly agents and promising anticancer leads..Nat Prod Rep2014;31:1202-26 PMCID:PMC4126874

[221] Field JJ,Paterson I,Díaz JF.Zampanolide, a microtubule-stabilizing agent, is active in resistant cancer cells and inhibits cell migration..Int J Mol Sci2017;18:E971 PMCID:PMC5454884

[222] Scheuer PJ,Madamba LA.The constituents of Tacca leontopetaloides..Lloydia1963;26:133-40

[223] Tinley TL,Leal RM,Cessac JW.Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity..Cancer Res2003;63:3211-20

[224] Lia J,Mooberry SL.Taccalonolide microtubule stabilizers..Bioorg Med Chem2014;22:5091-6 PMCID:PMC4099425

[225] Wang Y,Li GB,Wu C.Mechanism of microtubule stabilization by taccalonolide AJ..Nat Commun2017;8:15787 PMCID:PMC5467209

[226] Martín MJ,Fernández R,Rodríguez A.Isolation and first total synthesis of PM050489 and PM060184, two new marine anticancer compounds..J Am Chem Soc2013;135:10164-71

[227] Pera B,Pantazopoulou A,Matesanz R.New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanism..ACS Chem Biol2013;8:2084-94

[228] Manzoor S,Khan S,Iftikhar S.Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistance..Sci Rep2018;8:3305 PMCID:PMC5818492